Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial - Concepedia

Concepedia

Publication | Open Access

Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial

DOI Full Paper Access

81

Citations

23

References

2006

Year

Pedro Cahn, Jorge Villacian, Adriano Lazzarin, Christine Katlama, Beatriz Grinsztejn, Keikawus Arastéh, Nathan Clumeck, J Gerstoft, N.G. Stavrianeas, Santiago Moreno,

Clinical Infectious Diseases

Abstract

TPV/r had superior antiviral activity and increased immunologic benefits, compared with CPI/r, at week 24 among treatment-experienced patients infected with multidrug-resistant HIV-1.

References

	Year	Citations

Page 1